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Abstract
Background: Bone metastases occur frequently in advanced breast, lung, and prostate cancer, with approximately 70% of
patients affected. Pain is a major symptom of bone metastases, and current treatments may be inadequate or have unaccept-
able side effects. The mechanisms that drive cancer-induced bone pain are not fully understood; however, it is known that
there is sensitization of both peripheral bone afferents and central spinal circuits. It is well established that the N-methyl-D-
aspartate receptor plays a major role in the pathophysiology of pain hypersensitivity. Inhibition of the non-receptor tyrosine
kinase Src controls N-methyl-D-aspartate receptor activity and inhibiting Src reduces the hypersensitivity associated with
neuropathic and inflammatory pains. As Src is also implicated in osteoclastic bone resorption, we have investigated if
inhibiting Src ameliorates cancer-induced bone pain. We have tested this hypothesis using an orally bioavailable Src inhibitor
(saracatinib) in a rat model of cancer-induced bone pain.
Results: Intra-tibial injection of rat mammary cancer cells (Mammary rat metastasis tumor cells -1), but not vehicle, in rats
produced hindpaw hypersensitivity to thermal and mechanical stimuli that was maximal after six days and persisted for at
least 13 days postinjection. Daily oral gavage with saracatinib (20mg/kg) beginning seven days after intra-tibial injection
reversed the thermal hyperalgesia but not the mechanical allodynia. The analgesic mechanisms of saracatinib appear to be due
to an effect on the nervous system as immunoblotting of L2-5 spinal segments showed that mammary rat metastasis tumor
cells-1 injection induced phosphorylation of the GluN1 subunit of the N-methyl-D-aspartate receptor, indicative of receptor
activation, and this was reduced by saracatinib. Additionally, histology showed no anti-tumor effect of saracatinib at any dose
and no significant effect on bone preservation.
Conclusions: This is the first demonstration that Src plays a role in the development of cancer-induced bone pain and that
Src inhibition represents a possible new analgesic strategy for patients with bone metastases.
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Background
Cancer is the second leading cause of mortality world-
wide with three of the most common cancers (breast,
prostate, and lung) having a predilection to metastasize
to bone, favoring the axial skeleton (vertebrae, ribs, long
bones, and pelvis1–4). An estimated 70% of breast cancer
patients with advanced stage disease will be diagnosed
with bone metastases, which puts them at risk of skeletal-
related events, including pain, hypercalcemia, spinal cord
compression, decreased mobility, and fractures. It is esti-
mated that each year in the UK, there are 30,000 patients
with cancer-induced bone pain,5 which can be severe and
signiﬁcantly diminish patients quality-of-life. As the
tumor grows, breakthrough pain occurs and the
analgesic treatments available, including opioids, non-
steroidal anti-inﬂammatory drugs, bisphosphonates,
and radiotherapy, have limited eﬃcacy. As advances in
cancer therapeutics steadily increase the life expectancy
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of patients, including those with bone metastases, we
urgently need to develop new approaches in order to
provide mechanism-based therapies to better manage
cancer-induced pain.
Despite the high incidence of cancer-induced bone
pain, the mechanisms that initiate and maintain it are
still not completely understood. It is well known that
consequences of tumor growth include tissue damage,
release of inﬂammatory mediators, and injury to sensory
nerve ﬁber terminals in bone, all factors that contribute
to the inﬂammatory6 as well as the neuropathic7 compo-
nents of cancer-induced pain.8
Several animal models have been used to investigate
bone cancer pain,9–12 in which tumor cells are injected
directly into the tibia or femur of rodents, causing
changes in pain-related behaviors that are thought to
mimic bone pain. In animals with cancer-induced bone
pain, there are changes in both the central and peripheral
nervous system8,12–17 that contribute to synaptic plasti-
city in pain-related spinal cord neurons.18,19 This form of
synaptic plasticity involves activation of G-protein
coupled membrane receptors and intracellular signaling
pathways that converge on the protein tyrosine kinase
Src (Figure 1).
Src is a non-receptor protein tyrosine kinase that
plays a multitude of roles in cell signaling.20 It is
mainly present in osteoclasts,21 platelets,22 and neurons23
and is part of the N-methyl-D-aspartate (NMDA) recep-
tor complex23–26 in neurons. It has been widely demon-
strated that increased spinal NMDA receptor activity
leads to neuronal sensitization and ultimately to hyper-
sensitivity in diﬀerent pain models including bone cancer
pain19,27; phosphorylation of the GluN1 and GluN2B
subunits are thought to be the molecular drivers of this
hypersensitivity.14,28–30 Liu et al.31 showed that in
inﬂammatory and neuropathic pain states, blocking the
anchoring of Src with the NMDA receptor prevented the
phosphorylation-mediated enhancement of NMDA
receptors, resulting in reduced pain hypersensitivity.
Moreover, in the same study Src/ knockout mice
showed diminished central sensitization-mediated noci-
ceptive behaviors as well as impaired mechanical and
cold allodynia in neuropathic pain.31 As these mice had
normal behavioral responses to acute noxious stimuli,
Figure 1. Src regulation of NMDA receptors in spinal neurons. Spinal neuron NMDA receptors are physiologically blocked at the resting
potential due to a combination of Mg2þ block and dephosphorylation of protein tyrosine kinases. After intense nociceptive stimulation
neuropeptides such as substance P (SP) and calcitonin gene-related peptide (CGRP) are also released from small diameter afferents in
addition to glutamate. This causes activation of G-protein coupled receptors and initiates multiple intracellular signaling cascades, including
phospholipase C, protein kinase C, CAKb, and RACK1. These intracellular signaling cascades increase intracellular [Ca2þ] and converge on
the tyrosine kinase Src, which is phosphorylated. Src is thought to act as a hub for regulation of the NMDA receptor, and NMDA receptor
subunit phosphorylation leads to increased channel gating and increased NMDA receptor activity. This increased NMDA receptor activity
causes increased neuronal depolarization and sensitization (increased suprathreshold responsiveness, expanded receptive fields, sub-
threshold events are amplified), leading to pain hypersensitivity.
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Src function is thought to be crucial for pain hypersen-
sitivity but not for normal nociceptive processing.
Src activity is not speciﬁc for pain, as both preclinical
and clinical studies have reported that Src signaling is
involved in other processes, including bone cell activ-
ity.21,32 Src is highly expressed in osteoclasts and controls
bone resorption, and inhibiting Src activity33 precludes
osteoclast formation as well as preventing migration of
osteoclast precursors with subsequent formation of actin
ring and resorption pits.34 Additionally, mice lacking the
Src gene develop osteopetrosis, mainly due to impaired
osteoclastic function.35 It is interesting to note that
bisphosphonates, which inhibit osteoclast function, also
have some analgesic eﬃcacy in humans,36 and therefore,
controlling bone resorption could represent an avenue
for pain relief.
Despite all of these ﬁndings, the eﬀects of Src inhib-
ition on bone cancer pain remain to be established. We
hypothesized that it may be possible to reduce cancer-
induced bone pain using a Src inhibitor, which could
have the novel eﬀects of both reducing NMDA receptor
activity and inhibiting bone resorption. This may rep-
resent an innovative strategy to manage bone pain in
cancer patients. Here, we provide the ﬁrst demonstra-
tion that Src inhibition with saracatinib reduces pain
behaviors in a rat model of bone cancer pain, and
that this is associated with reduced phosphorylation
of spinal GluN1 receptors and reduced osteoclast
activity.
Materials and methods
Experimental animals
Male Sprague Dawley rats (Harlan, 200–225 g at time of
surgery) were used for the study. All animal procedures
were authorized by the UK Home Oﬃce and were in
accordance with International Association for the
Study of Pain guidelines. Animals were assigned to
groups by randomization and a group size of n¼ 8 was
used for all studies on the basis of power calculations.
The researcher performing the experiments was blind to
the grouping of individual animals until the end of the
experiment, although the physical appearance of saraca-
tinib when used for gavage is such that the vehicle and
lowest dose (2mg/kg) can be distinguished from higher
concentrations (5 and 20mg/kg).
Cell preparation
Syngeneic mammary rat metastasis tumor cells-1
(MRMT-1; Riken, Japan) were cultured in Rosewell
Park Memorial Institute 1640 with 10% foetal bovine
serum, 1% L-glutamine, and 2% penicillin/streptomycin.
On the day of surgery, cells were suspended in Hank’s
buﬀer to achieve the ﬁnal concentration of 3 103 cells/
5l and kept on ice.
Cell injection
Rats were anaesthetized with 2% isoﬂurane in oxygen
and a dental drill was used to bore a hole in the
antero-medial surface of the left distal tibia. Cells were
injected using a Hamilton syringe, and the hole was
sealed using bone wax followed by bone cement. After
irrigation with 0.9% saline, the wound was closed using
sutures. The sham group underwent the same procedure
but the animals received injection of Hank’s buﬀer
instead of tumor cells. After the surgery, animals recov-
ered after 24 h before behavioral testing.
Behavioral assessment
Prior to surgery, all animals had baseline tests of gait37
nociceptive sensitivity to measure paw withdrawal
thresholds and latency in response to mechanical38 and
heat39 stimuli. After surgery animals were allowed to
recover for 24 h and gait, paw withdrawal thresholds
and latencies were measured at repeated intervals post-
surgery. Behavioral testing of nociceptive sensitivity was
performed on the plantar surface of the left hindpaw
using calibrated von Frey ﬁlaments to measure paw
withdrawal threshold, determined using the up-down
method,40 and radiant heat stimuli for measurements
of paw withdrawal latency.
Bone analysis
At the end of the experiment, tibias were collected and
prepared for tumor volume and bone analysis using
histomorphometry. Brieﬂy, left and right tibia were iso-
lated, muscle removed and the bones were ﬁxed in 4%
paraformaldehyde for two days. Bones were then dec-
alciﬁed for three weeks in ethylenediaminetetraacetic
acid, paraﬃn embedded, sectioned, and mounted
onto slides. Total tumor area was measured on
four nonserial H&E-stained histological sections and
average tumor area/bone (TV/BV) calculated using
Osteomeasure (Osteometrics, Decatur, GA, USA)
software.
Pharmacokinetics
Whole blood was obtained via cardiac puncture under
terminal pentobarbital (200mg/kg i.p.) anaesthesia and
centrifuged (4C for 5min at 11,000 rpm) to separate the
plasma, which was frozen at 80C until use.
Saracatinib levels were measured by liquid chromatogra-
phy-mass spectrometry (Charles River, Tranent, UK)
using a API5000 mass spectrometer (AB Sciex,
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Ontario, Canada). The lower limit of the assay was
0.5 ng/ml and the upper limit was 5,000 ng/ml.
Western blotting
Proteins were extracted from the dorsal L2-5 segments
of the spinal cord in lysis buﬀer (RIPA buﬀer plus
phosphatase inhibitor; PhosSTOP, Roche) with an
ultrasonicator on ice, and cleared of cellular debris
and nuclei by centrifugation at 14,000 relative centri-
fugal force for 15min at 4C. Extracted proteins (25 mg
per well) were loaded and separated by standard 3%
to 8% Tris-Acetate gel. Proteins were transferred to
polyvinylidene diﬂuoride membranes and then blocked
with 5% (w/v) dried milk in TBS-T for 1 h at room
temperature. The blots were incubated overnight at
4C using the following antibodies that were diluted
in TBS-T containing 5% dried milk: phosphorylated
GluN1 (Ser896) 1:10,000 (Millipore, cat # ABN88);
GluN1 1:1,000 (Millipore cat# AB9864R); phosphory-
lated Src (Tyr418) 1:800 (Abcam, cat# ab4816); Src
1:800 (Abcam, cat# ab47405). The following day, the
primary antibody was bound with a goat anti-rabbit
secondary antibody that was conjugated to horseradish
peroxidase (Cell signaling, cat #7074-S) and the signal
detected by enhanced chemiluminescence. Each
phosphoprotein was normalized to the expression of
the corresponding total protein on the same mem-
brane. Densitometric analyses were performed using
Image J software.
Bone biomarker analysis
Under terminal pentobarbital (200mg/kg, i.p.) anesthe-
sia, whole blood was obtained by cardiac puncture and
centrifuged (4C, 2000 rpm for 15min), TRAP5b and
procollagen type 1 N-terminal propeptide (P1NP) were
measured by ELISA (Immuno diagnostic systems,
ELISA kit for TRAP5b cat# SB-TR102 and PNP1 cat#
AC-33F1) using 100 ml samples of serum according to the
manufacturer instructions.
Compounds
Saracatinib was provided by AstraZeneca. The doses
chosen were based on previous rat studies where saraca-
tinib was shown to inhibit Src kinase in tumor tissue
in vivo. Pharmacokinetic studies have shown that there
is some central nervous sytem (CNS) penetration with
saracatinib in rats with cerebrospinal ﬂuid (CSF) levels
being about 3% of plasma levels. The vehicle for sara-
catinib was a mixture of 0.5% hydroxypropyl methyl
cellulose (Fluka)þ 0.1% polysorbate (Tween 80;
Fluka), sterilized by autoclaving at 121C for 20min at
30 psi (1.5 Bar).
Statistical analysis and data presentation
Data are shown as means and the standard error of the
mean ( SEM) of three rats (for Western blotting) or
eight animals (for in vivo behavioral studies). Statistical
evaluation was performed by Mann Whitney test and
one- or two-way analysis of variance (ANOVA), fol-
lowed by appropriate post hoc tests. The a priori level
of signiﬁcance at 95% conﬁdence level was considered at
p< .05.
Results
Saracatinib inhibits thermal hyperalgesia in a rat
model of bone cancer pain
We used a rat model of bone cancer pain to study the
eﬀect of Src inhibition on gait, paw withdrawal latency
to heat stimuli, and paw withdrawal thresholds to mech-
anical stimulation. Rats received intra-tibia injection of
mammary cancer cells MRMT-1 (3 103 in 5 mL) and
gait analysis as well as behavioral responses to mildly
noxious mechanical and thermal stimuli applied to the
hindpaw were determined prior to and at diﬀerent time
points post-injections. Compared to Hanks buﬀer-
injected controls, there was no signiﬁcant change in
either the area of the aﬀected paw that was used
during locomotion, or the pressure applied to the paw
during the step cycle in animals that had intra-tibial
MRMT-1 cell injections (data not shown). In our
hands, ﬂinching and guarding were not reproducible
ﬁndings in MRMT-1 treated rats, and there was no
qualitative diﬀerence between control and treated ani-
mals. Nonetheless, MRMT-1 injected rats showed
time-dependent, signiﬁcant (p< .05, two-way ANOVA)
reductions in hindpaw withdrawal latency to thermal
stimuli and in mechanical withdrawal threshold relative
to the Hank’s buﬀer-treated controls (Figure 2 (a) and
(b)). Signs of hypersensitivity were detectable as early as
Day 1 post-MRMT-1 injection, were well established by
Day 6 and persisted to at least Day 13 postsurgery.
In order to examine the eﬀect of Src inhibition on the
MRMT-1-induced hypersensitivity, rats were treated
daily with saracatinib by gavage for seven days (either
2, 5, or 20mg/kg, n¼ 8/group), beginning seven days
after MRMT-1 or Hank’s buﬀer injection. Saracatinib
is an orally bio-available, small molecule that inhibits
Src and Bcr-Abl.41 Saracatinib (20mg/kg, p.o. for
seven days) fully reversed cancer-induced heat hyperalge-
sia (Figure 3(a)), but lower doses were ineﬀective (data
not shown). Daily injection of saracatinib (20mg/kg but
not 2 or 5mg/kg) in MRMT-1 tumor-bearing rats
resulted in withdrawal latencies that were signiﬁcantly
(p< .05, two-way ANOVA) elevated relative to
those measured in MRMT-1/vehicle-treated rats
(Figure 3(a)). None of the doses of saracatinib used
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were able to reduce tactile allodynia (Figure 3(b)).
Administration of saracatinib (20mg/kg, p.o.) to
Hank’s buﬀer-treated animals did not produce any
change in either paw withdrawal latency or paw with-
drawal threshold (Figure 3(a) and (b)), indicating that
saracatinib does not inhibit normal nociceptive
processing.
Increasing the dosing duration of animals treated with
20mg/kg of saracatinib from 7 to 11 days had no eﬀect
on tactile allodynia (p> .7, two-way ANOVA, data not
shown). Pharmacokinetic studies of diﬀerent saracatinib
doses and exposure times (measured from plasma sam-
ples taken at the end of the dosing period) showed a
nonlinear relationship between plasma saracatinib con-
centration and dose, and in the 20mg/kg group increas-
ing the dosing duration from 7 to 11 days did not
produce any additional increase in plasma saracatinib
levels (p> .05; one-way ANOVA; Figure (4)).
Saracatinib has good oral bioavailability and a t1/2 of
approximately 7 h in rats; plasma levels taken 24 h after
7 or 11 days daily dosing at 20mg/kg demonstrated free
levels of saracatinib> 50Ki for Src kinase (Ki 2.7 nM).
In addition, from previous studies in rats, the CSF
exposure of saracatinib is 3% of total plasma levels
which would provide compound exposure in the CNS
of at least 10Ki for Src at trough. Hence, based on
the known pharmacokinetics in rats, plasma protein
binding and the measured saracatinib exposure data in
these studies, levels of saracatinib are expected to inhibit
Src kinase in peripheral tissues and the CNS by 100% for
the 24-h period after daily oral dosing. Therefore, its
failure to reduce mechanical allodynia is unlikely to be
due simply to sub-optimal administration, in terms of
either frequency or dose.
Taken together, these studies showed that inhibiting
Src selectively abolishes heat hyperalgesia in a model of
cancer-induced bone pain but does not aﬀect normal
nociceptive processing. Tactile allodynia was unaﬀected
by Src inhibition, even when the dosing period was
extended, suggesting diﬀerent underlying mechanisms
in the pathophysiology of thermal hyperalgesia versus
tactile allodynia in bone cancer pain.
Saracatinib reduces spinal GluN1 receptor
phosphorylation in cancer-induced bone pain
Saracatinib could have its eﬀect on behavior in cancer-
induced bone pain by an action on nociceptive circuits
within the nervous system or by preserving bone due to
reduced osteoclastic resorption. Src is widely expressed
in the nervous system, being enriched in the cerebral
cortex, hippocampus, brainstem, cerebellum, and
Figure 2. Pain-related behavior after intra-tibia MRMT-1 injection. (a) Mean (1 SEM) paw withdrawal latency to radiant heat stimulation
of the ipsilateral plantar hindpaw in animals injected with either MRMT-1 cells or vehicle in the left tibia (n¼ 8/group). The MRMT-1
injection was performed on day 0 (indicated by the dashed line). Asterisks indicate significant differences (p< 0.05; 2-factor repeated-
measures ANOVA followed by Tukey’s test post hoc) between the MRMT-1 and vehicle injected rats. (b) Mean (1 SEM) 50% paw
withdrawal thresholds to graded mechanical stimulation in the same animals as shown in (a). Asterisks indicate significant differences
between MRMT-1 and vehicle injected animals (p< 0.05; 2-factor repeated-measures ANOVA followed by Tukey’s test post hoc).
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Figure 3. Reversal of heat hyperalgesia by Src inhibition in cancer-induced bone pain. Daily gavage with saracatinib (20mg/kg) reversed
the heat hyperalgesia (a), but not the mechanical allodynia (b) of cancer-induced bone pain. Symbols show mean 1 SEM paw withdrawal
latencies to radiant heat stimulation (a) or 50% withdrawal thresholds to graded mechanical stimulation (b). Animals (n¼ 8/group) received
an intra-tibial injection of either MRMT-1 cells or Hanks buffer vehicle on day 0 (gray line) followed by daily administration of either
saracatinib or vehicle starting on day 7 (black line). Lower doses of saracatinib (2 and 5mg/kg) were ineffective (data not shown). Asterisks
indicate significant differences between MRMT-1 injected animals treated with either saracatinib or vehicle (p< 0.05; 2-factor repeated-
measures ANOVA followed by Tukey’s test post hoc).
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spinal cord.22,42 The eﬀect(s) of saracatinib could poten-
tially occur at several levels within the nervous system,
and the current study was not designed to elucidate its
speciﬁc site of action. Instead, we have investigated
whether MRMT-1 cell injection modulated Src activity
and/or downstream signaling pathways in the Src cascade
in the nervous system, and if treatment with saracatinib
could modulate this activity. Because the ﬁrst synapse in
nociceptive pathways is found in the spinal dorsal horn,
we studied Src and GluN1 activation in the spinal cord.
MRMT-1 cells or Hank’s buﬀer were injected into the
left tibia and seven days later rats were treated either
with saracatinib (20mg/kg, p.o.) or vehicle (1ml/kg,
p.o.) by daily gavage. In a terminal experiment, the
dorsal horn from the left L2-5 segments of the spinal
cord was harvested at either 1, 6, 8, 11, or 13 days post-
intratibial injection for immunoblotting analysis of phos-
phorylation of Src and GluN1, an NMDA receptor
subunit that is downstream of Src (Figure 5(a)
and (b)). About 40% of the aﬀerents that innervate the
tibia originate from the L3 dorsal root ganglion with the
remainder being scattered across the L2–L5 ganglia.43
Most of the spinal neurons activated by acute noxious
stimulation of the tibia are in the L3 and L4 spinal
segments44; therefore, to ensure that as much of the
innervation of the tibia was analyzed, we used L2–L5
spinal segments in the blotting experiments.
Intra-tibial injection of MRTM-1 cancer cells, but not
Hank’s buﬀer, resulted in a signiﬁcant (p< .05, Mann
Whitney test) increase in Src phosphorylation that was
detectable one day postinjection and remained elevated
up to the last time point studied, Day 13 (Figure 5(a)).
Similarly, phosphorylation of the GluN1 subunit was
signiﬁcantly increased (p< .05, Mann Whitney test)
in MRMT-1 treated rats from Day 1 to at least
Day 13 (Figure 5(b)). Daily treatment with saracatinib
(20mg/kg, p.o.), but not vehicle, in MRMT-1 tumor
bearing rats signiﬁcantly (p< .05) reduced phosphory-
lated Src to levels comparable to that observed in
Hank’s buﬀer-injected rats (Figure 5(a)). Expression of
phosphorylated Src was reduced (59% change compared
to MRMT-1 treated rats) within 24 h of the ﬁrst saraca-
tinib dose (Day 8 post intra-tibial injection), and this
eﬀect was maintained throughout the full administration
period (observable on Days 11 and 13 post-intra-tibia
injection, 52% and 87% change compared to MRMT-
1 treated rat, respectively; Figure 5(a)). Importantly, sar-
acatinib also signiﬁcantly decreased phosphorylation of
the GluN1 subunit of the NMDA receptor (Figure 5(b)).
Similar to the inhibition of MRMT-1-induced Src phos-
phorylation with 20mg/kg saracatinib daily, phosphor-
ylation of GluN1 was reduced within one day of the ﬁrst
dose and this persisted throughout the duration of the
study (Figure 5(b)).
Here, we demonstrate that animals with behavioral
signs of cancer-induced bone pain show increased acti-
vation (phosphorylation) of Src and the GluN1 subunit
of the NMDA receptor in segments of the lumbar spinal
cord that are known to receive primary aﬀerents from
the tibia.17,43,44 We conﬁrm with immunoblotting that
saracatinib-inhibited spinal Src in vivo, as it reduced
MRMT-1 induced Src phosphorylation, and import-
antly, saracatinib also reduced GluN1 phosphorylation
in the spinal dorsal horn whilst also reversing heat hyper-
algesia behavior at the whole animal level. Overall, this
suggests that the Src-inhibitor saracatinib has a major
eﬀect on the nervous system and, therefore, potential
eﬃcacy as an analgesic in cancer-induced bone pain.
Src inhibition has minimal effects on inhibiting bone
resorption
In order to establish whether the eﬀects of saracatinib on
behavior were in part due to the bone-preserving eﬀects
of Src-inhibition, we investigated bone histology and
biomarkers of bone turnover. The left tibia of rats was
inoculated with MRMT-1 cells or Hanks’ buﬀer and the
animals treated by daily gavage with saracatinib (2, 5, or
20mg/kg) seven days later for a further seven days. At
the end of the experiment, tibias were collected and pro-
cessed for bone histomorphometry to determine eﬀects
on tumor and bone volume/integrity. Saracatinib,
including the 20mg/kg dose known to reduce pain-
related behaviors, did not have any eﬀect on tumor
growth in the tibia (Figure (6)). Additionally, analysis
of bone turnover biomarkers showed that saracatinib
Figure 4. Pharmacokinetics of Saracatinib in vivo. Box plots of
plasma saracatinib concentration measured by high-performance
liquid chromatography following dosing at 2, 5, or 20mg/kg daily
for 7 days and at 20mg/kg for 11 days. The horizontal line within
the box is the median, the box boundaries are the 25th and 75th
percentiles, and the error bars show the data range. There is a
nonlinear relationship between saracatinib dose and plasma levels
but extending the treatment duration from 7 to 11 days at 20mg/
kg did not increase the plasma concentration of the drug (p> 0.05,
ANOVA).
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dose-dependently reduced serum levels of tartrate-resis-
tant acid phosphatase tartarate-resistant acid phospha-
tise (TRACP5b), an enzyme highly expressed by bone
resorbing osteoclasts (Figure 7(a)). Seven days of sara-
catinib administration (5 or 20mg/kg, p.o. daily) signiﬁ-
cantly (p< .05, one-way ANOVA) reduced serum levels
of TRACP5b in tumor-bearing rats compared to tumor-
bearing rats that received vehicle (Figure 7(a)).
Saracatinib at 2mg/kg, p.o. had no signiﬁcant eﬀect
(p¼ .22, one-way ANOVA; Figure 7(a)). No signiﬁcant
diﬀerence was observed in serum levels of P1NP
(a marker of osteoblast activity) in tumor bearing rats
following treatment with saracatinib (2, 5, or 20mg/kg,
p.o. per seven days) when compared to vehicle treated
rats (p¼ .49, p¼ .52, and p¼ .71, respectively; one-way
ANOVA; Figure 7(b)). These data show that whilst sar-
acatinib at a dose that reverses heat hyperalgesia behav-
iorally does reduce bone resorption, it has no signiﬁcant
Figure 5. Saracatinib inhibits GluN1 phosphorylation in spinal dorsal horn. Injection of MRMT-1 into the left tibia of rats resulted in
increased phosphorylation at the spinal level of the nonreceptor tyrosin kinase Src (a) and of the NMDA receptor subunit GluN1 (b), as
determined by Western blotting and band densitometry, b-actin was used as an additional loading control (c). Saracatinib (20mg/kg/day,
p.o.) treatment significantly (p< 0.05, Mann-Whitney test) reversed phosphorylation of Src (a) in a time-dependent manner and signifi-
cantly (p< 0.05, Mann-Whitney test) reduced phosphorylation of GluN1 within 24 h from the first injection (b). Blot label: C¼ control;
d¼ day; v¼ vehicle; s¼ saracatinib.
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eﬀect on bone formation, suggesting that the antiresorp-
tive eﬀect of saracatinib has only a minor role in its eﬃ-
cacy as a potential analgesic.
Discussion
The present study demonstrates that Src inhibition has
the potential to play a role in reducing cancer-induced
bone pain. Intratibial injection of MRMT-1 cancer cells
has previously been shown to cause thermal hyperalgesia
and mechanical allodynia of the skin,10,17 and here we
show that inhibiting Src reverses MRMT-1 induced cuta-
neous heat hyperalgesia, probably due to an action on the
nervous system. Additionally, we showed that the anal-
gesic eﬀect of saracatinib is not due to inhibition of tumor
growth, and it is also independent of its eﬀects on bone.
Figure 6. Saracatinib has no effect on MRMT-1 tumor growth. Photomicrographs of haematoxylin and eosin (H&E) stained decalcified
sections of tibia injected with either vehicle (a) or MRMT-1 cells (b, c). Low power images of whole bones (ai, bi, ci) show the normal
marrow in the control group and the extent of tumor growth in the MRMT-1 injected groups 13 days after injection (arrowheads in bi and ci).
As can be seen in (c), saracatinib 20mg/kg p.o. for seven days had no effect on tumor cell growth. Higher magnification images show the drill
hole (aii, bii, cii) and the marrow spaces (aiii) and the tumor-bone interface (biii,ciii). Quantitative analysis of multiple sections through the tibia
showed that saracatinib had no significant effect on tumor growth (d) at any dose tested. Bars show meanþ 1 SD with n¼ 3/group.
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Technical considerations
The current study used behavioral testing of the plantar
hindpaw skin to infer the presence of bone pain. Cancer
patients with bone metastases report altered skin sensa-
tion overlying sites of skeletal disease when compared to
control sites45; the majority of patients reported
increased skin sensitivity in response to pinprick or
warm stimuli, but brushing and cool hyperesthesia
were also reported and the heat hyperalgesia and mech-
anical allodynia observed in the current study is consist-
ent with this. In cancer patients, there was no attempt to
relate the proximity/area of abnormal skin sensation to
the location/size of the skeletal metastasis,45 the skin sen-
sory changes can cover up 140 cm2,45 indicating that
cancer-induced bone pain evokes a zone of secondary
hyperalgesia in the overlying skin that can spread over
a considerable area, and this could account for why
tumor cells growing in the rat distal tibia cause behav-
ioral changes to plantar skin stimulation. Many previous
animal studies of cancer-induced bone pain have used
the surrogate measure of behavioral changes to mildly
noxious cutaneous stimuli to infer the presence of bone
pain, with a few studies assessing noncutaneous behav-
ioral changes such as weight-bearing, grip strength, and
rotarod tolerance. Use of a Hank’s buﬀer control shows
that the behavioral changes to cutaneous stimulation are
not simply a postsurgical eﬀect, and we, therefore,
assume that they reﬂect the eﬀects of the tumor cells
within the tibia. It is interesting to note that of the 31
studies of cancer-induced bone pain in the literature
where MRMT-1 cells were used in rats,46 28 studies
used cutaneous stimuli applied to the plantar foot as a
surrogate measure for bone pain, 2 did not report any
behavioral testing, and only 1 used deep tissue stimula-
tion (mechanical pressure on the antero-medial surface
of the distal tibia47) but there was no comparative plan-
tar skin testing in that study.
Role of Src in the nervous system in cancer-induced
bone pain
In rodents it is known that cancer-associated pain is
associated with increased phosphorylation of Src,
GluN1, and GluN2B in spinal cord, and that these
changes are thought to contribute to the generation
and maintenance of pain.30,48,49 We conﬁrmed that
intra-tibial MRMT-1 injection evokes phosphorylation
of spinal GluN1 receptors using an antibody to the
S896 site of the GluN1 receptor; importantly, we show
that GluN1 phosphorylation is inhibited by Saracatinib
at a dose that reverses heat hyperalgesia. We interpret
the increased GluN1 phosphorylation as receptor activa-
tion and conclude that Saracatinib reduces GluN1 acti-
vation by inhibiting Src, but the precise relationship
between S896 phosphorylation and pain is unknown.
Because Src is a molecular point of convergence through
which a variety of intracellular signaling cascade and
cell-surface receptors enhance NMDA receptor function,
its activation has been implicated in the synaptic plasti-
city that is required for physiological processes such as
learning and memory as well as pathological events like
persistent pain.23–26,31 Long-term potentiation (LTP)
plays a key role in long-lasting increases in synaptic
transmission and one of the major mechanisms of LTP
is by the actions of NMDA receptors on ion currents. It
has been shown that altering Src functioning by intracel-
lular administration of Src blockers inhibits LTP induc-
tion.50 Changes in synaptic transmission as a result of
NMDA receptor upregulation is also crucial in the mal-
adaptive plasticity associated with pathological
Figure 7. Effects of Src inhibition on bone turnover. Treatment
with saracatinib for seven days (2, 5, or 20mg/kg/day, p.o.) signifi-
cantly (p< 0.05, one-way ANOVA) reduced the serum levels of
TRACP-5b (a) in a dose dependent manner. However, daily injec-
tion of saracatinib did not change the serum levels of PNP1 (b).
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conditions such as persistent pain. Woolf and Salter19
have described how spinal dorsal horn nociceptive neu-
rons are hyper-responsive in several pain models as a
result of enhanced NMDA receptor activity, which is
critical for the initiation and maintenance of increased
neuronal responsiveness. Thus, the analgesic eﬀect of
saracatinib might be due to inhibition of the direct acti-
vation/phosphorylation of the GluN1 NMDA receptor
subunit.
Consistent with previous reports,29 we have demon-
strated that spinal levels of phosphorylated Src and
GluN1 are elevated in rats with tumor in bone compared
to sham animals. Inhibiting GluN1 phosphorylation
with either a protein kinase A inhibitor51 or antisense
oligodeoxynucleotides52 reduced some of the behavioral
signs of neuropathic and inﬂammatory pain in earlier
studies. Although GluN1 phosphorylation was reduced
by Saracatinib in the present study and, therefore, may
be important in cancer associated bone pain, other tar-
gets downstream from Src may also be involved. We
attempted quantitative immunoblotting of the phos-
phorylated form of the GluN2B subunit of the NMDA
receptor using a Tyr1472-phospho GluN2B antibody
and by immunoprecipitation using a pan-phosphory-
lated antibody followed by a GluN2B subunit antibody.
GluN2B is implicated in the mechanisms of chronic pain
as preventing its phosphorylation reverses inﬂammatory
pain hypersensitivity30 and blocking spinal GluN2B sub-
units reduced hyperalgesia/allodynia in the MRMT-1
model of cancer-induced bone pain.14 Despite previous
results with the Tyr1472-phospho GluN2B antibody,14
we were unable to demonstrate reproducible high-quality
immunoblotting of phosphorylated GluN2B and immu-
noprecipitation was also unsuccessful.
Previous studies have shown that altering Src activity
aﬀects behavioral responses to diﬀerent modalities of
noxious stimuli equally: heat and mechanical hyperalge-
sia in a model of inﬂammatory pain were both reduced in
mice when Src was decoupled pharmacologically from
the NMDA receptor and Src/ knockout mice
show reduced hyperalgesia to both mechanical and
cold stimuli in a model of neuropathic pain.31
However, in the current study, Saracatinib only reversed
heat hyperalgesia, having no eﬀect on mechanical allo-
dynia. We assume that there is a causal relationship
between inhibition of Src/GluN1 phosphorylation and
reversal of heat hyperalgesia by Saracatinib in treated
MRMT-1 rats, but current models of central sensitiza-
tion would predict that when postsynaptic NMDA
receptor activity is reduced, hypersensitivity to all types
of noxious stimuli would be aﬀected.19 One speculative
explanation for the observation that Saracatinib did not
ameliorate mechanical allodynia relates to Src expression
in functionally speciﬁc groups of nociceptive neurons.
It is an unwritten assumption that Src is expressed
equally in all neurons at the same anatomic location,
but which might have diﬀerent functional properties.
This is probably an incorrect generalization on the
basis of Src immunocytochemical labeling in the
cortex, where it is clear that even though there is
strong staining of layer V pyramidal neurons, not all
neurons are labeled.22 There are no immunocytochem-
ical studies of Src in the spinal cord, but there is no a
priori reason to assume that all nociceptive spinal neu-
rons express Src equally. It is known from previous
in vivo studies of spinothalamic and spinoparabrachial
neurons that functionally speciﬁc subgroups of nocicep-
tive neurons exist.53,54 While the most frequently
encountered nociceptive cell types respond to several dif-
ferent stimulus modalities (heat, cold, mechanical, etc.),
a subset selectively responsive to noxious mechanical sti-
muli is well documented.53 Perhaps, the neurons that
receive just noxious mechanical inputs express less Src
than those that receive both mechanical and heat inputs
and, therefore, are less likely to be inhibited by
Saracatinib. This could be tested in future anatomical
studies.
Src inhibition and bone turnover
Previous studies in mice lacking the c-Src proto-onco-
gene have shown that Src expression is necessary for
normal bone resorption, as these animals develop osteo-
petrosis,35 and the most critical role for c-Src in bone is
related to osteoclast function rather than diﬀerenti-
ation.55 There is no diﬀerence in the number of formed
osteoclasts between wild type and Src/ knockout mice;
however, in Src/ knockout mice, osteoclasts failed to
form ruﬄed borders, resulting in a limited ability to
resorb bone matrix.55 In vitro studies suggested that
Src also regulates the life span of the osteoclast, thus
aﬀecting bone resorption.56,57 In contrast however,
Src/ knockout mice showed equal or higher numbers
of osteoclasts than wildtype mice, suggesting that in vivo
there is a compensating mechanism from other members
of the Src kinase family.35 In accordance with these pre-
vious reports showing that Src inhibition inﬂuences the
activity of osteoclasts and not their numbers, the data
from our study demonstrate that saracatinib, in a dose
dependent manner, reduced the level of the systemic
bone resorption marker TRACP5b, similar to the eﬀects
observed in patients with advanced cancer.58 Clinical
dose escalation studies with saracatinib have shown
that doses of 50 to 175mg/day, which are well tolerated
in humans with solid tumors, produce a reduction in
bone resorption markers including TRAP5b without
altering tumor burden.55,58 Therefore, these data suggest
that Src kinase inhibition reduces bone turnover in both
species and acts as a biomarker of Src inhibition in these
studies. In contrast with other reports in which
Felice et al. 11
disruption of Src activity enhanced osteoblast diﬀerenti-
ation and bone-forming activity,59 in our study saracati-
nib treatment had no eﬀect on P1NP serum levels of
tumor-bearing rats. Although saracatinib reduced osteo-
clast activity, this ﬁnding did not translate to bone pres-
ervation, potentially due to the very aggressive nature of
the model with high numbers of osteoclasts at the tumor-
bone interface. It has been demonstrated that saracatinib
reduces tumor growth in a c-Src-transfected 3T3-
ﬁbroblast xenograft model in vivo41; however, in our
study, seven days of saracatinib treatment failed to inﬂuence
the tumor growth in the tibia at any of the doses tested,
further suggesting that the antihyperalgesic eﬀect observed
of saracatinib is independent of tumor volume, and it is
mainly mediated by its eﬀects on the nervous system.
Conclusion
These ﬁndings demonstrate a role for Src in bone
cancer pain and indicate that inhibition of Src through
saracatinib may represent a novel strategy for reducing
bone cancer pain. Critically, the eﬀects of saracatinib
on pain behaviors seem mainly due to its eﬀects on the
nervous system, by inhibiting phosphorylation of Src
and GluN1, and not due to an antitumor or bone pre-
serving eﬀect of the drug. This suggests that a better
understanding of how NMDA receptors subunits are
implicated in development and maintenance of bone
cancer pain may lead to more mechanism-speciﬁc thera-
peutic strategies.
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